Trial Profile
A Long-Term Extension Study to Demonstrate Safety of Tildrakizumab in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Psoriatic arthritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sun Pharma Global FZE; Sun Pharmaceutical Industries
- 24 Jan 2024 Status changed from active, no longer recruiting to completed.
- 28 Dec 2023 Planned End Date changed from 15 Dec 2023 to 8 Jan 2024.
- 04 Dec 2023 Planned End Date changed from 31 Oct 2023 to 15 Dec 2023.